Business News • PR NewsWire • Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis

Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis

Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis

TARRYTOWN, N.Y. and PARIS, April 24, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicine Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing...

View More : http://www.prnewswire.com/news-releases/regeneron-and-sanofi-receive-positive-chmp-opinion-for-kevzara-sarilumab-to-trea...

Releted News by prnewswire

NGM Bio Announces NGM282 Dramatically Reduced Liver Fat and Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial

IBM Study: Four Ways to Achieve Maximum ROI in Enterprise Mobility

Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI)

SunPower to Supply Equipment Solutions to Global Solar Power Plant Market